(OA13) Stereotactic Radiosurgery and Concurrent Targeted Therapy: Improving the Response Rate for Breast Cancer Brain Metastasis

The use of HER2-directed monoclonal antibodies has changed the landscape of patients with HER2-positive breast cancer. Despite the increase in overall survival with the use of agents such as trastuzumab, the drug ’s poor penetration through the blood-brain barrier leaves the brain particularly vulnerable to disease relapse. In contrast, lapatinib, a dual HER2/EGFR small molecule tyrosine kinase inhibitor (TKI), has demonstrated greater penetration through the blood brain barrier, but evidence of its clinic al use in patients with CNS metastases is limited.

Source: International Journal of Radiation Oncology * Biology * Physics - May 3, 2018 Category: Radiology Authors: Joseph M. Kim, Joseph M. Kim, Jacob A. Miller, Rupesh Kotecha, Samuel T. Chao, Manmeet S. Ahluwalia, David M. Peereboom, Alireza M. Mohammadi, Gene H. Barnett, Erin S. Murphy, Michael A. Vogelbaum, Lilyana Angelov, Jame Abraham, Halle C.F. Moore, G. Thoma Tags: Oral Abstract Source Type: research